Info on Eosinophilic Diseases and COVID-19

  • Eosinophilic Gastrointestinal Diseases (EGID) are not immunodeficiency disorders.
  • The medical literature does not support a concerning association between eosinophil-associated diseases and coronaviruses.  
  • There is no known increased risk for viral infections in patients with EGID. 
  • Patients on eosinophil-depleting drugs, such as benralizumab, mepolizumab, and reslizumab, as well as patients on dupilumab, have not been reported to have an increased risk of viral infections and / or complications from viral infections.
  • Patients with eosinophilia have not been reported to have an increased risk of viral infections.
  • Eosinophils are not the primary cells involved in protective immunity against viruses.
  • Topical glucocorticoids (fluticasone and budesonide) are not systemically immunosuppressive, unlike prednisone, which is systemically immunosuppressive.
  • A caveat to this information concerns rare EGID and other eosinophilic syndromes that may have other underlying disease components, such as immunosuppression induced by systemic steroids such as prednisone; these patients may have increased risk for complications. Such patients should consult with their primary doctor for specific advice and guidance. 
  • It is important to emphasize that we do not have substantial data to demonstrate that there is increased risk of harm with COVID-19 when EGID or hypereosinophilic syndromes are present.

Research Participants

  • Patients in research studies should make personal decisions about the risk / reward of continuing to participate and adhere to local and national health department guidelines regarding travel and preparedness.
  • Subjects with concurrent viral-like illnesses should reschedule their study visits.
  • If you have specific questions regarding your trial related to the known risks of the COVID-19 virus, contact your specific research trial team.